AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12648031
Drug: Fluvastatin (20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin (20-40 mg/day, or 40 mg twice daily)
Trial: 12648031
Drug: Lovastatin (20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin (20-40 mg/day, or 40 mg twice daily)
Trial: 12648031
Drug: Pravastatin (10-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (10-40 mg/day)
Trial: 8590530
Drug: Simvastatin (10-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (10-40 mg/day)
Trial: 10638663
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 50 mg/kg body weight in 5% dextrose
Trial: 10638663
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 50 mg/kg + rutin 5 mg/kg in 5% dextrose
Trial: 9402073
Drug: HIV vaccine
RxNorm normalized name: AAV-2 HIV Vaccine
DrugBank: TGAAC09 (DB06363)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV vaccine intervention
Trial: 3965439
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of haloperidol
Trial: 17888803
Drug: CALM intervention
RxNorm normalized name: Eucerin Calming Itch Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CALM intervention (education and behavioral activation delivered by anxiety clinical specialists, with options for cognitive-behavioral therapy, antianxiety medications, or both)
Trial: 9660534
Drug: Granisetron plus
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron plus methylprednisolone (250 mg i.v. twice daily)
Trial: 9660534
Drug: Granisetron alone
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron alone (3 mg i.v. over 30 s)
Trial: 8704424
Drug: Zhong Feng
RxNorm normalized name: Feng Mi
DrugBank: Honey (DB14242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zhong Feng I oral liquor (acute stage), Zhong Feng II oral liquor (convalescent stage) and Western medicine
Trial: 2515723
Drug: Deprenyl 10
RxNorm normalized name: (11C)L-deprenyl-D2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deprenyl 10 mg per day
Trial: 24791510
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of small needle knife and Daqinjiu Tang
Trial: 21330911
Drug: ALVAC with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALVAC with Remune and ALVAC alone (combined vaccine groups)
Trial: 30353603
Drug: Musical training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Musical training (weekly 45-min lessons for 52 weeks)
Trial: 21225098
Drug: Oral dabigatran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dabigatran 220 mg once-daily
Trial: 17764540
Drug: Subcutaneous enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous enoxaparin 40 mg once-daily
Trial: 17356145
Drug: High-energy extracorporeal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-energy extracorporeal shock-wave therapy
Trial: 17356145
Drug: Low-energy extracorporeal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-energy extracorporeal shock-wave therapy
Trial: 15359161
Drug: Wide diameter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wide diameter implants (5.0 and 6.0 mm)
Trial: 15359161
Drug: Standard diameter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard diameter implants (3.75 and 4.0 mm)
Trial: 11123735
Drug: Diazepam, 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam, 0.4 mg x kg(‐1)
Trial: 7989502
Drug: Onapristone 5
RxNorm normalized name: Onapristone
DrugBank: Onapristone (DB12637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onapristone 5 mg/day
Trial: 7989502
Drug: Onapristone 15
RxNorm normalized name: Onapristone
DrugBank: Onapristone (DB12637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onapristone 15 mg/day
Trial: 7989502
Drug: Onapristone 50
RxNorm normalized name: Onapristone
DrugBank: Onapristone (DB12637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onapristone 50 mg/day
Trial: 7989502
Drug: Post-treatment (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-treatment (after discontinuation of onapristone)
Trial: 7989502
Drug: Luteal phase
RxNorm normalized name: Nuphar lutea leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteal phase post-treatment
Trial: 5579489
Drug: Gradual withdrawal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gradual withdrawal of anticholinergic drugs over four weeks
Trial: 5579489
Drug: Abrupt withdrawal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abrupt withdrawal of anticholinergic drugs
Trial: 5579489
Drug: Stable levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Stable levodopa therapy with anticholinergic drugs
Trial: 28264826
Drug: Computer-determined dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-determined dosage of insulin (CDD) using the STAR-GRYPHON model
Trial: 28264826
Drug: Bedside titration:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedside titration: insulin dose determined by medical staff
Trial: 28264826
Drug: Standard care:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care: insulin dose and frequency of blood glucose testing determined by medical staff
Trial: 23206182
Drug: Rivastigmine monotherapy
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine monotherapy
Trial: 23206182
Drug: Rivastigmine combination
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine combination therapy
Trial: 23206182
Drug: Memantine in
RxNorm normalized name: memantine Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine in combination therapy
Trial: 8569424
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg orally each evening for 1 week
Trial: 1910730
Drug: Perioperative and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative and postoperative steroid use
Trial: 369651
Drug: Dummy tablets
RxNorm normalized name: cholecalciferol / tricalcium phosphate Chewable Tablet [Caltrate Gummy Bites]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dummy tablets (control)
Trial: 31519527
Drug: Psychosocial variables
RxNorm normalized name: Ferric carbonate, ferric hydroxide, ferrous hydroxide (variable mixture)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychosocial variables (including religiosity, knowledge regarding blood donation process, overall quality of life, blood donation of peers, sociodemographic variables, fear of blood, injections, and fainting)
Trial: 23319135
Drug: Clinofibrate (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinofibrate (all doses)
Trial: 21881066
Drug: Protease inhibitor
RxNorm normalized name: Protease inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitor (PI)-based HAART
Trial: 21881066
Drug: Nonnucleoside reverse
RxNorm normalized name: OraVerse
DrugBank: Phentolamine (DB00692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonnucleoside reverse transcriptase inhibitor-based HAART (without PI)
Trial: 29311704
Drug: Ramipril 5
RxNorm normalized name: ramipril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril 5 mg/day
Trial: 17446306
Drug: Pregabalin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (200 mg tid for 3 weeks)
Trial: 11104592
Drug: Early postoperative
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early postoperative gastric supply of nutrients (Osmolite, Ross; first 3 hours 30 ml/h and second 3 hours 50 ml/h; total 240 ml after 6 hours)
Trial: 11104592
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (crystalloid solutions only)
Trial: 8142781
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream (eutectic mixture of local anesthetics) applied for 3 minutes
Trial: 2873397
Drug: Oral B
RxNorm normalized name: bran ORAL BOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral B subunit killed whole‐cell (BS‐WC) vaccine
Trial: 2873397
Drug: Killed whole‐cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Killed whole‐cell (WC) vaccine
Trial: 15670563
Drug: Oral methionine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral methionine administration
Trial: 8947993
Drug: Bromfenac 5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromfenac 5, 10, 25, 50, or 100 mg
Trial: 31564057
Drug: Dupilumab with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab with topical corticosteroids
Trial: 22039269
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection (CS injection)
Trial: 20929584
Drug: Individual Dietary
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual Dietary and Activity Planning (IDAP) - goal-setting with a daily reduction of 600 kcal
Trial: 10771456
Drug: Ziprasidone 40
RxNorm normalized name: ziprasidone 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone 40 mg day(‐1) on days 9‐11 followed by 80 mg day(‐1) on days 12‐15
Trial: 9387729
Drug: Zhenkeling oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zhenkeling oral liquor (ZKL group)
Trial: 9387729
Drug: Pectoral syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pectoral syrup (control group)
Trial: 1343611
Drug: Weekly oral
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly oral low-dose (7.5 mg) methotrexate (MTX) for 2 years
Trial: 1343611
Drug: Weekly oral
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly oral low-dose (7.5 mg) methotrexate (MTX)
Trial: 2864738
Drug: Gastric inhibitory
RxNorm normalized name: Gastric inhibitory peptide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastric inhibitory polypeptide (GIP) in pharmacological doses
Trial: 2864738
Drug: Cholecystokinin (CCK)
RxNorm normalized name: cholecystokinin
DrugBank: Cholecystokinin (DB08862)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecystokinin (CCK) in pharmacological doses
Trial: 2864738
Drug: Somatostatin in
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin in pharmacological doses
Trial: 30880951
Drug: batefenterol 37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: batefenterol 37.5 µg
Trial: 30880951
Drug: batefenterol 75
RxNorm normalized name: Batefenterol
DrugBank: Batefenterol (DB12526)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: batefenterol 75 µg
Trial: 30880951
Drug: batefenterol 150
RxNorm normalized name: Batefenterol
DrugBank: Batefenterol (DB12526)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: batefenterol 150 µg
Trial: 30880951
Drug: batefenterol 300
RxNorm normalized name: Batefenterol
DrugBank: Batefenterol (DB12526)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: batefenterol 300 µg
Trial: 30880951
Drug: batefenterol 600
RxNorm normalized name: Batefenterol
DrugBank: Batefenterol (DB12526)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: batefenterol 600 µg
Trial: 30880951
Drug: umeclidinium/vilanterol (UMEC/VI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: umeclidinium/vilanterol (UMEC/VI) 62.5/25 µg
Trial: 24344049
Drug: Mangifera indica
RxNorm normalized name: MANGIFERA INDICA SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mangifera indica extract (Vimang tablets, 900 mg/day) combined with methotrexate (MTX, 12.5 mg/week)
Trial: 24344049
Drug: Methotrexate (MTX,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (MTX, 12.5 mg/week) without Vimang extract
Trial: 17474183
Drug: Cholinergic agents
RxNorm normalized name: ANTICHOLINERGIC AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholinergic agents
Trial: 17474183
Drug: NMDA agonists
RxNorm normalized name: NMDA
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NMDA agonists
Trial: 17474183
Drug: Cognitive interventions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive interventions including rehabilitation pharmacotherapy
Trial: 17474183
Drug: Drugs strategically
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs strategically coupled to cognitive-behavioral treatments
Trial: 16136052
Drug: Chemotherapy started
RxNorm normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chemotherapy started within 3 months of surgery (CMF, CMF i.v., cyclofosfamide, epirubicin, and 5‐fluorouracil)
Trial: 16136052
Drug: Chemotherapy started
RxNorm normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chemotherapy started after 3 months of surgery (delayed start)
Trial: 12182269
Drug: Patients' expectancies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients' expectancies of treatment effectiveness
Trial: 2140838
Drug: Ketanserin 40
RxNorm normalized name: ketanserin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin 40 mg/day (KE40)
Trial: 2140838
Drug: Ketanserin 80
RxNorm normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin 80 mg/day (KE80)
Trial: 507944
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment and oral administration of BCG
Trial: 28397242
Drug: Ibrutinib with
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ibrutinib with concomitant anticoagulant or antiplatelet agents (175 patients)
Trial: 28397242
Drug: Ibrutinib alone
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ibrutinib alone (without anticoagulants or antiplatelets)
Trial: 26362110
Drug: Oral collagen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral collagen peptide supplementation
Trial: 15307407
Drug: Community-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based intervention to improve skills of village drug kit managers
Trial: 10392251
Drug: Fibrin glue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrin glue treatment
Trial: 6441014
Drug: Standard polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard polyethylene catheter plus heparin
Trial: 6441014
Drug: Polyurethane catheter
RxNorm normalized name: polyurethane-62
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyurethane catheter without heparin
Trial: 30879111
Drug: Received cumulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Received cumulative dose over time
Trial: 30270762
Drug: Intensive aphasia
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive aphasia therapy
Trial: 24820104
Drug: Complete immunization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete immunization schedule (7 vaccines and 15 doses)
Trial: 21987582
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids (prednisolone sodium phosphate, 1.0%)
Trial: 17567657
Drug: Oral amoxicillin
RxNorm normalized name: amoxicillin Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amoxicillin for 7 days (n = 126)
Trial: 15718308
Drug: C‐HART (70.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C‐HART (70.6 Gy) with concurrent FU (600 mg/m(2), 120 hours continuous infusion) and MMC (10 mg/m(2))
Trial: 2676220
Drug: Etidocaine 1%
RxNorm normalized name: etidocaine 1% preservative-free injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etidocaine 1% at 2 mg.kg‐1
Trial: 2676220
Drug: Bupivacaine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 1.5 mg.kg‐1
Trial: 22078153
Drug: LDA plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDA plus naproxen/esomeprazole magnesium (500 mg naproxen and 20 mg esomeprazole magnesium, twice daily on days 6-10)
Trial: 22078153
Drug: LDA plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDA plus placebo (81 mg LDA once daily on days 1-5 and placebo twice daily on days 6-10)
Trial: 11289473
Drug: Metformin (2,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (2,550 mg/day for 14 days)
Trial: 11289473
Drug: Metformin (0.1-0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (0.1-0.5 microg/ml) in pooled human plasma
Trial: 1080961
Drug: Intravenous high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous high dose methotrexate and leucovorin rescue
Trial: 28557555
Drug: β1 blocker
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: β1 blocker nebivolol
Trial: 23140546
Drug: Statin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin treatment in current smokers (n=129)
Trial: 19543892
Drug: Cervical TFESI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical TFESI using triamcinolone (particulate steroid)
Trial: 19543892
Drug: Cervical TFESI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical TFESI using dexamethasone (non-particulate steroid)
Trial: 22392497
Drug: Peach shake
RxNorm normalized name: AVOBENZONE 2.7 g in 100 g / OCTINOXATE 6 g in 100 g TOPICAL LIPSTICK [GOLDEN ROSE GLOW KISS TINTED LIP BALM PEACH SHAKE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peach shake meal (PSM) (SA: 0.06 ± 0.001 mg/100 g)
Trial: 15774433
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT), 12-14 sessions
Trial: 9469276
Drug: Intraumbilical oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraumbilical oxytocin (20 IU in 20 mL of saline)
Trial: 9469276
Drug: Intraumbilical saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraumbilical saline (20 mL)
Trial: 8535640
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of sulphasalazine (SASP) and methotrexate (MTX)
Trial: 2404049
Drug: Low-fat diet
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat diet intervention (15% of energy intake) with bi-weekly individual counseling sessions
Trial: 11483335
Drug: Androgen ablation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen ablation (goserelin 3.6 mg every 4 weeks and flutamide 250 mg t.i.d. for 2 months before and during radiation therapy)
Trial: 24461613
Drug: Indacaterol (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indacaterol (150 μg)
Trial: 21225011
Drug: Preseasonal prophylactic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preseasonal prophylactic treatment with antihistamines (2-4 weeks before pollen season)
Trial: 7637479
Drug: Injected polio
RxNorm normalized name: poliovirus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injected polio vaccine (IPV)
Trial: 2491766
Drug: Corticosteroids plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids plus thyrotropin-releasing hormone (TRH)
Trial: 870513
Drug: Ovine prolactin
RxNorm normalized name: prolactin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovine prolactin (25 mg)
Trial: 22159928
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 ml normal saline)
Trial: 870513
Drug: Ovine prolactin
RxNorm normalized name: prolactin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovine prolactin (100 mg)
Trial: 26666324
Drug: Novel oral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel oral anticoagulants (NOACs) including dabigatran etexilate, rivaroxaban, apixaban, and edoxaban.
Trial: 26666324
Drug: Classic anticoagulants
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classic anticoagulants like heparin, low‐molecular‐weight heparins (LMWHs), fondaparinux, and vitamin K antagonists.
Trial: 21199290
Drug: 200 mcg
RxNorm normalized name: CrM 200 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mcg sublingual misoprostol
Trial: 21199290
Drug: 600 mcg
RxNorm normalized name: Biotin 600 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mcg sublingual misoprostol
Trial: 24365208
Drug: Intramuscular oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular oxytocin (10 IU)
Trial: 16409193
Drug: Grass allergen
RxNorm normalized name: orchardgrass allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grass allergen tablet (SQ-T) at various doses (25,000 to 1,000,000 standardized quality tablet)